Recent Advances in Immunotherapy for Patients with Head and Neck Cutaneous Squamous Cell Carcinoma
Cutaneous squamous cell carcinoma (CSCC) is the second most common non-melanoma skin cancer. A majority of patients present with localized disease, but some can present with locally advanced or metastatic disease. Most of these advanced cases occur in the anatomical head and neck region and are asso...
Main Authors: | Adam Khorasanchi, Richard Wu, Kari Kendra, Claire Verschraegen |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-10-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/14/21/5325 |
Similar Items
-
Impact of p16 Status and Anatomical Site in Anti-PD-1 Immunotherapy-Treated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Patients
by: Kate Clancy, et al.
Published: (2021-09-01) -
Diagnostic Predictors of Immunotherapy Response in Head and Neck Squamous Cell Carcinoma
by: Piero Giuseppe Meliante, et al.
Published: (2023-02-01) -
Rapid response to cemiplimab for advanced cutaneous squamous cell carcinoma
by: Hanieh Zargham, MD, et al.
Published: (2022-08-01) -
Immunotherapy to Avoid Orbital Exenteration in Patients With Cutaneous Squamous Cell Carcinoma
by: Luke S. McLean, et al.
Published: (2022-01-01) -
Cutaneous angiosarcoma: A review of current evidence for treatment with checkpoint inhibitors
by: Lucy Guan, et al.
Published: (2023-03-01)